At the news
? BEARISHIMPACT 8/10 8-K filed Apr 20, 2026 at 07:56 ET
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer due to futility, based on an independent data monitoring committee's recommendation. Additionally, Gilead will not extend its option rights to Arcus's early-stage pipeline programs beyond July 14, 2026, retaining only limited existing options.
- Phase 3 STAR-121 study evaluating domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo in first-line metastatic NSCLC discontinued due to futility
- Decision based on pre-planned futility analysis by Independent Data Monitoring Committee (IDMC); safety not assessed at this stage
- Exploratory endpoint showed zimberelimab + chemo performed consistently with pembrolizumab + chemo on overall survival
- Phase 2 EDGE-Lung study also being discontinued
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access